Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models.


Journal

Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 02 12 2022
accepted: 19 02 2023
medline: 1 5 2023
pubmed: 22 3 2023
entrez: 21 3 2023
Statut: ppublish

Résumé

Topical imiquimod based creams are indicated as immune stimulants for papillomas and various skin neoplasms. Imiquimod is considered a TLR7 ligand. These creams are also used in research to induce skin inflammation in mice as a model for psoriasis. We observed that this inflammatory response was not strictly imiquimod dependent and we set out to establish which components drive the proinflammatory effects. To this end, we examined the induction response in a BALB/cJRj mouse model, in which 50 mg of cream is applied to 2 cm

Identifiants

pubmed: 36943539
doi: 10.1007/s10787-023-01175-3
pii: 10.1007/s10787-023-01175-3
doi:

Substances chimiques

Imiquimod P1QW714R7M
isostearic acid X33R8U0062
Toll-Like Receptor 7 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

799-812

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Bergfeld et al (2018) Safety assessment of fatty acids and soaps as used in cosmetics. In: The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. [Online]. Available: http://www.cir-safety.org/supplementaldoc/preliminary-search-engines-and
Bourgognon J, Suessmilch M, McColl A, Cavanagh J (2019) Abstract #4297 blood brain barrier breakdown following topical aldara treatment. Brain Behav Immun 81:24–25. https://doi.org/10.1016/j.bbi.2019.08.086
doi: 10.1016/j.bbi.2019.08.086
Brück J, Dringen R, Amasuno A, Pau-Charles I, Ghoreschi K (2018) A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol 27(6):611–624. https://doi.org/10.1111/exd.13548
doi: 10.1111/exd.13548 pubmed: 29603404
Butchi NB, Pourciau S, Du M, Morgan TW, Peterson KE (2008) Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists. J Immunol 180(11):7604–7612. https://doi.org/10.4049/jimmunol.180.11.7604
doi: 10.4049/jimmunol.180.11.7604 pubmed: 18490763
Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M (2018) Scanning the immunopathogenesis of psoriasis. 19(1)
CIR (2013) Safety assessment of fatty acids and fatty acid salts as used in cosmetics
De Paula D, Martins CA, Bentley MVLB (2008) Development and validation of HPLC method for imiquimod determination in skin penetration studies. Biomed Chromatogr 22(12):1416–1423. https://doi.org/10.1002/bmc.1075
doi: 10.1002/bmc.1075 pubmed: 18655215
Del Rosso JQ (2005) The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis 76(4):241–248
pubmed: 16315560
Flutter B, Nestle FO (2013) TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol 43(12):3138–3146. https://doi.org/10.1002/eji.201343801
doi: 10.1002/eji.201343801 pubmed: 24254490
Girolomoni G et al (2017) The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 31(10):1616–1626. https://doi.org/10.1111/jdv.14433
doi: 10.1111/jdv.14433 pubmed: 28653490 pmcid: 5697699
Global Report on Psoriasis (2023)
Graceway Pharmaceuticals (2009) Center for drug evaluation and pharmacology review: 201153Orig1s000
Hawkes JE, Gudjonsson JE, Ward NL (2017) The snowballing literature on imiquimod-induced skin inflammation in mice: a critical appraisal. J Invest Dermatol 137(3):546–549. https://doi.org/10.1016/j.jid.2016.10.024
doi: 10.1016/j.jid.2016.10.024 pubmed: 27955901
Horváth S, Komlódi R, Perkecz A, Pintér E, Gyulai R, Kemény Á (2019) Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice. Sci Rep 9(1):1–8. https://doi.org/10.1038/s41598-019-39903-x
doi: 10.1038/s41598-019-39903-x
Horváth S, Kemény Á, Pintér E, Gyulai R (2020) A localized aldara (5% imiquimod)–induced psoriasiform dermatitis model in mice using Finn chambers. Curr Protoc Pharmacol 90(1):1–12. https://doi.org/10.1002/cpph.78
doi: 10.1002/cpph.78
Jabeen M et al (2020) Advanced characterization of imiquimod-induced psoriasis-like mouse model. Pharmaceutics 12(9):1–18. https://doi.org/10.3390/pharmaceutics12090789
doi: 10.3390/pharmaceutics12090789
Luo D, Wu H, Zhao Y, Liu J, Wang F (2016) Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models. 1733–1738. https://doi.org/10.1177/1535370216647183
McColl A, Thomson CA, Nerurkar L, Graham GJ, Cavanagh J (2016) TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain. J Neuroinflammation 13(1):1–16. https://doi.org/10.1186/s12974-016-0562-2
doi: 10.1186/s12974-016-0562-2
Nakajima K, Sano S (2018) Mouse models of psoriasis and their relevance. J Dermatol 45(3):252–263. https://doi.org/10.1111/1346-8138.14112
doi: 10.1111/1346-8138.14112 pubmed: 29226571
Nerurkar L, Mccoll A, Graham G, Cavanagh J (2017) The systemic response to topical aldara treatment is mediated through direct TLR7 stimulation as imiquimod enters the circulation. Sci Rep. https://doi.org/10.1038/s41598-017-16707-5
doi: 10.1038/s41598-017-16707-5 pubmed: 29185473 pmcid: 5707416
Pockros PJ et al (2007) Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 47(2):174–182. https://doi.org/10.1016/j.jhep.2007.02.025
doi: 10.1016/j.jhep.2007.02.025 pubmed: 17532523
Schön MP, Schön M (2007) Imiquimod: mode of action. Br J Dermatol 157(SUPPL. 2):8–13. https://doi.org/10.1111/j.1365-2133.2007.08265.x
doi: 10.1111/j.1365-2133.2007.08265.x pubmed: 18067624
Schön MP, Schön M, Klotz KN (2006) The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 126(6):1338–1347. https://doi.org/10.1038/sj.jid.5700286
doi: 10.1038/sj.jid.5700286 pubmed: 16575388
Straß S, Schwamborn A, Keppler M, Guse J, Burnet M (2021) Synthesis, characterization and in vivo distribution of intracellular delivered macrolide SCFA derivatives. 1–16. https://doi.org/10.1002/cmdc.202100139
Sun L et al (2018) Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles. Int J Nanomed 13:5625–5635. https://doi.org/10.2147/IJN.S170832
doi: 10.2147/IJN.S170832
Telò I, Pescina S, Padula C, Santi P, Nicoli S (2016) Mechanisms of imiquimod skin penetration. Int J Pharm 511(1):516–523. https://doi.org/10.1016/j.ijpharm.2016.07.043
doi: 10.1016/j.ijpharm.2016.07.043 pubmed: 27452419
van den Höfel N (2018) Basiscreme DAC. https://flexikon.doccheck.com/de/Basiscreme_DAC#
van der Fits L et al (2009) Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 182(9):5836–5845. https://doi.org/10.4049/jimmunol.0802999
doi: 10.4049/jimmunol.0802999 pubmed: 19380832
Walter A et al (2013) Aldara activates TLR7-independent immune defence. Nat Commun 4(1):1–13. https://doi.org/10.1038/ncomms2566
doi: 10.1038/ncomms2566
Wolff F, Loipetzberger A, Gruber W, Esterbauer H, Aberger F, Frischauf AM (2013) Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation. Oncogene 32(50):5574–5581. https://doi.org/10.1038/onc.2013.343
doi: 10.1038/onc.2013.343 pubmed: 23995793 pmcid: 3898320
Yang K, Oak ASW, Elewski BE (2021) Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol 22(2):173–192. https://doi.org/10.1007/s40257-020-00578-0
doi: 10.1007/s40257-020-00578-0 pubmed: 33301128
Zhang D et al (2022) Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between caucasians and asians: a systematic review and meta-analysis. Front Med 8(January):1–9. https://doi.org/10.3389/fmed.2021.814938
doi: 10.3389/fmed.2021.814938

Auteurs

Simon Straß (S)

Pharmaceutical Chemistry, Institute for Pharmaceutical Sciences, Eberhard Karls University Tübingen, Tübingen, Germany.
Synovo GmbH, Tübingen, Germany.

Johanna Geiger (J)

Synovo GmbH, Tübingen, Germany.

Mariella Martorelli (M)

Pharmaceutical Chemistry, Institute for Pharmaceutical Sciences, Eberhard Karls University Tübingen, Tübingen, Germany.
Synovo GmbH, Tübingen, Germany.

Sophia Geiger (S)

Synovo GmbH, Tübingen, Germany.

Natascha Cloos (N)

Synovo GmbH, Tübingen, Germany.

Manuel Keppler (M)

Synovo GmbH, Tübingen, Germany.

Tina Fischer (T)

Synovo GmbH, Tübingen, Germany.

Laura Riexinger (L)

Synovo GmbH, Tübingen, Germany.

Anna Schwamborn (A)

Synovo GmbH, Tübingen, Germany.

Jamil Guezguez (J)

Synovo GmbH, Tübingen, Germany.

Nadja Späth (N)

Synovo GmbH, Tübingen, Germany.

Santiago Cruces (S)

Synovo GmbH, Tübingen, Germany.

Jan-Hinrich Guse (JH)

Synovo GmbH, Tübingen, Germany.

Thaisa Lucas Sandri (TL)

Synovo GmbH, Tübingen, Germany.
Institute of Tropical Medicine, Eberhard Karls University Tübingen, Tübingen, Germany.

Michael Burnet (M)

Synovo GmbH, Tübingen, Germany. michael.burnet@synovo.com.

Stefan Laufer (S)

Pharmaceutical Chemistry, Institute for Pharmaceutical Sciences, Eberhard Karls University Tübingen, Tübingen, Germany.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
C-Reactive Protein Humans Biomarkers Inflammation
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

Classifications MeSH